ACC 2022: Late-breaking Science Video Collection

Published: 05 April 2022

  • Views:

    Views Icon 4069
  • Likes:

    Heart Icon 7
View Transcript

Overview

Our regular review series View from the Thoraxcenter hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provide a concise analysis of the late-breaking science results and spotlight impactful data. 

For a deeper dive into key clinical trial data, Dr Harriette Van Spall (McMaster University, Hamilton, CA)talks with principal investigators in her regular Late-Breaker Discussion Series

Short, accessible Expert Interviews were conducted with select faculty focusing on the results, applicability, and impact on future research.

More from this programme

Part 1

View from the Thoraxcenter

In this concise episode of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their analysis of the late-breaking trials that will be presented at ACC 2022.

Part 3

Expert Interviews

Faculty Biographies

Pim van der Harst

View full profile

Marie-Sophie de Koning

View full profile

Transcript

- I'm Pim van der Harst, principal investigator of this trial and affiliated with the University Medical Centre, Utrecht.

- I'm Marie-Sophie De Koning. I'm the PhD candidate and a lead author of the Groningen Intervention Study for the Preservation of Cardiac Function with Sodium Thiosulfate after Myocardial Infarction, affiliated with the University Medical Center Groningen.

Study Objectives

- This is a trial that we designed after a lot of experimental data that looked very promising. So there were cellular data from mice, from rats, from pigs, from dogs, that all looked very promising in the preservation of myocardial infarction.

Study Design and Patient Cohort

- The study was designed as a randomised, multicentre, placebo-controlled trial and the patients, 380 patients, were enrolled, presenting with a first STEMI and they had to have ongoing complaints and/or ST-deviation, directly after arrival at the cath lab. They were assigned to receive either sodium thiosulfate, twelve and a half grams intravenously, or matching placebo and they received a second dose six hours later.

Study Results

We observed that the mean infarct size in the placebo group was 8.9%, in the sodium thiosulfate group, mean infarct size was 8%. So, we did not observe a reduction in infarct size between groups, between arms.

Take-home Messages for Clinicians

- Well, of course, the outcome was very disappointing but I think we still learned a lot. It is very difficult to design trials in the ischaemia reperfusion arena but it still has potential opportunities in other settings, for example, in the chronic heart failure or other conditions that have been tested experimentally but it shows us just how difficult it is to translate animal experimental findings to real clinical benefits.

Further Study Recommendations

So, further studies in the acute setting. In the Netherlands, the STEMI network is so efficient that patients are presenting within 90 minutes on efforts, so the average infarct size was also below 9%. So, we don't know whether this might be beneficial when they're presenting at a later time, when there is more, longer duration of ischaemia. And we also do not know whether it might be beneficial in long-term treatment.